Literature DB >> 6192836

Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here?

K D Bagshawe.   

Abstract

An overview of the application of markers for solid tumours is presented. Some of the potential problems with general cancer tests are considered as well as the ways in which the more specific markers have been applied. The limited specificities of markers defined so far remain a serious limitation but they have found useful clinical application. Their use in radioimmunolocalisation provides an interesting challenge to the physical methods of tumour localisation and the possibilities of drug targeting by antibodies are as exciting as the difficulties are formidable. It is, I suggest, a field that will continue to evolve and be productive.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6192836      PMCID: PMC2011455          DOI: 10.1038/bjc.1983.172

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  50 in total

1.  Subacute pulmonary hypertension due to chorionepithelioma.

Authors:  K D BAGSHAWE; W D BROOKS
Journal:  Lancet       Date:  1959-03-28       Impact factor: 79.321

2.  The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies.

Authors:  D PRESSMAN; L KORNGOLD
Journal:  Cancer       Date:  1953-05       Impact factor: 6.860

3.  Design and performance characteristics of a whole-body positron transaxial tomograph.

Authors:  E J Hoffmann; M E Phelps; N A Mullani; C S Higgins; M M Ter-Pogossian
Journal:  J Nucl Med       Date:  1976-06       Impact factor: 10.057

4.  Macrophage-electrophoretic-mobility (M.E.M.) test for malignant disease. An independent confirmation.

Authors:  J A Pritchard; J L Moore; W H Sutherland; C A Joslin
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

5.  Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen.

Authors:  F J Primus; R H Wang; D M Goldenberg; H J Hansen
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

6.  Choriocarcinoma scanning using radiolabeled anti-body to chorionic gonadotrophin.

Authors:  J Quinones; G Mizejewski; W H Beierwaltes
Journal:  J Nucl Med       Date:  1971-02       Impact factor: 10.057

7.  Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody.

Authors:  D M Herlyn; Z Steplewski; M F Herlyn; H Koprowski
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

8.  Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody.

Authors:  P A Farrands; A C Perkins; M V Pimm; M J Embleton; J D Hardy; R W Baldwin; J D Hardcastle
Journal:  Lancet       Date:  1982-08-21       Impact factor: 79.321

9.  Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody.

Authors:  R H Begent; P A Keep; A J Green; F Searle; K D Bagshawe; R F Jewkes; B E Jones; G M Barratt; B E Ryman
Journal:  Lancet       Date:  1982-10-02       Impact factor: 79.321

10.  A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasms.

Authors:  C J Menendez-Botet; H F Oettgen; C M Pinsky; M K Schwartz
Journal:  Clin Chem       Date:  1978-06       Impact factor: 8.327

View more
  10 in total

1.  Tumour markers in testicular cancer.

Authors:  P A Light
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

2.  In vitro and in vivo studies of the production of placental proteins (HCG, SP1, PPs) in human choriocarcinoma cell lines.

Authors:  S Sekiya; N Inaba; H Ishige; H Takamizawa; H Bohn
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

3.  Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

Authors:  C D Estin; U S Stevenson; G D Plowman; S L Hu; P Sridhar; I Hellström; J P Brown; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

4.  Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.

Authors:  S K Sharma; J A Boden; C J Springer; P J Burke; K D Bagshawe
Journal:  Cell Biophys       Date:  1994

5.  The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.

Authors:  R B Pedley; J A Boden; R W Boden; A Green; G M Boxer; K D Bagshawe
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

Review 6.  The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

7.  The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.

Authors:  R G Melton; F Searle; R F Sherwood; K D Bagshawe; J A Boden
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

8.  Antibody directed enzymes revive anti-cancer prodrugs concept.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

9.  Immunoreactive inhibin-like material in serum and gastric juice of patients with benign and malignant diseases of the stomach.

Authors:  S A Shanbhag; A R Sheth; S A Nanivadekar; N A Sheth
Journal:  Br J Cancer       Date:  1985-06       Impact factor: 7.640

10.  N1-methylnicotinamide level in the blood after nicotinamide loading as further evidence for malignant tumor burden.

Authors:  K Nakagawa; M Miyazaki; K Okui; N Kato; Y Moriyama; S Fujimura
Journal:  Jpn J Cancer Res       Date:  1991-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.